ReachMD CME

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/future-frontiers-the-future-landscape-of-alzheimers-therapeutics/26348/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/comparative-efficacy-subq-vs-intravenous-dmts-in-alzheimers-disease/26347/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-insights-navigating-the-use-and-challenges-of-disease-modifying-therapies/26346/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-the-latest-data-on-ad-disease-modifying-therapies/26345/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/markers-of-memory-pathological-biomarkers-of-clinical-mci-due-to-ad/26344/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/precision-imaging-mris-critical-role-in-early-mci-ad-diagnosis/26343/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/beyond-guesswork-validated-methods-for-mci-assessment-in-alzheimers-diagnosis/26342/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/inequity-and-illness-understanding-mci-disease-course-and-severity-for-racial-minorities/26341/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-subtle-onset-understanding-early-mci-ad-symptoms/26340/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/dementia-on-a-spectrum-preclinical-stages-of-mci-in-ad/26339/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

CME credits: 0.50 Valid until: 23-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/ Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL. In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can …

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-transfusion-independence-with-jak-inhibitor-therapy/26509/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-anemia/26508/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/pacritinib-for-myelofibrosis-across-the-cytopenic-spectrum/26507/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-ruxolitinib-intolerance-or-resistance-in-myelofibrosis/26506/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-and-when-to-manage-ruxolitinib-failure/26505/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-to-use-prognostic-risk-scoring-and-symptom-burden-assessment-to-tailor-myelofibrosis-treatment/26504/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients. Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.